Evidence map›Paper›PMID 34275893›Full record

ArticleCancer biomarkers : section A of Disease markers2021

Genetic and epigenetic landscape of leukocyte infiltration identifies an immune prognosticator in lung adenocarcinoma.

Seema Khadirnaikar, Annesha Chatterjee, Sudhanshu Kumar Shukla

Abstract read
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Seema KhadirnaikarDepartment of Biosciences and Bioengineering, Indian Institute of Technology Dharwad, Dharwad, Karnataka, India.
Annesha ChatterjeeDepartment of Biosciences and Bioengineering, Indian Institute of Technology Dharwad, Dharwad, Karnataka, India.
Sudhanshu Kumar ShuklaDepartment of Biosciences and Bioengineering, Indian Institute of Technology Dharwad, Dharwad, Karnataka, India.
Indian Institute of Technology Dharwad · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLeukocyte infiltration plays an critical role in outcome of various diseases including Lung adenocarcinoma (LUAD).

objectivesTo understand the genetic and epigenetic factors affecting leukocyte infiltration and identification and validation of immune based biomarkers.

methodCorrelation analysis was done to get the associations of the factors. CIBERSORT analysis was done for immune cell infiltration. Genetic and epigenetic analysis were performed. Cox regression was carried out for survival.

resultsWe categorized the TCGA-LUAD patients based on Leukocyte fraction (LF) and performed extensive immunogenomic analysis. Interestingly, we showed that LF has a negative correlation with copy number variation (CNV) but not with mutational load. However, several individual genetic mutations, including KRAS and KEAP1, were significantly linked with LF. Also, as expected, patients with high LF showed significantly increased expression of genes involved in leukocyte migration and activation. DNA methylation changes also showed a strong association with LF and regulated a significant proportion of genes associated with LF. We also developed and validated an independent prognostic immune signature using the top six prognostic genes associated with LF.

conclusionTogether, we have identified clinical, genetic, and epigenetic variations associated with LUAD LF and developed an immune gene-based signature for disease prognostication.

Indexed as

Adenocarcinoma of LungBiomarkers, TumorHumansLeukocytesLung NeoplasmsPrognosisSurvival AnalysisBiomarkers, TumorImmune landscapeleukocyte fractionLung adenocarcinomaprognosis

Identifiers

PMID34275893
PMCPMC12500205
OpenAlexW3182047577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.